We are live on ! Find out more
MCMC

Matrix Capital Management Company Portfolio holdings

AUM $46.3M
1-Year Est. Return 114.38%
This Fund
S&P 500
This Quarter Est. Return
+12.9%
1 Year Est. Return
+114.38%
3 Year Est. Return
+245.06%
5 Year Est. Return
+259.19%
10 Year Est. Return
+1,887.32%
AUM
$57.6M
AUM Growth
-$49.1M
Cap. Flow
-$61.4M
Cap. Flow %
-106.6%
Top 10 Hldgs %
100%
Holding
3
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
MAZE
Maze Therapeutics
MAZE
+$40.3M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$21.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AURA icon
1
Aura Biosciences
AURA
$725M
$37.7M 65.48%
6,922,870
– –
MAZE
2
Maze Therapeutics
MAZE
$1.51B
$19.9M 34.52%
480,000
-1,173,684
-71% -$40.3M
ZNTL icon
3
Zentalis Pharmaceuticals
ZNTL
$332M
– –
-13,959,973
Closed -$21.1M

Similar funds

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
RRC
Range Rock Capital Wellesley, Massachusetts $46.7M AUM
NPCM
New Paradigm Capital Management Great Falls, Virginia $46.8M AUM
FCM
Firsthand Capital Management San Jose, California $46.9M AUM 114.33% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
EGI
EAM Global Investors Solana Beach, California $47.1M AUM 320.45% 1-Year Est. Return
IPHI
Inflection Point Holdings II New York $47.3M AUM
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Matrix Capital Management Company's Q4 2025 Portfolio in Review

As of Q4 2025, Matrix Capital Management Company held 3 positions worth $57.6M, down 46% from $107M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Matrix Capital Management Company withdrew a net $61.4M in Q4 2025, closing 1 position and reducing 1 holding. Its most notable exit was Zentalis Pharmaceuticals, an estimated $21.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Matrix Capital Management Company's biggest Q4 2025 reduction was Maze Therapeutics, cutting an estimated $40.3M.
  • Matrix Capital Management Company fully exited Zentalis Pharmaceuticals in Q4 2025, selling an estimated $21.1M.
  • Matrix Capital Management Company's ten largest holdings make up 100% of its $57.6M portfolio in Q4 2025.
  • Matrix Capital Management Company opened 0 new positions and closed 1 in Q4 2025.
  • Matrix Capital Management Company's portfolio value fell 46% quarter-over-quarter to $57.6M.

Based on Matrix Capital Management Company's 13F filing for Q4 2025, filed 13 Feb 2026.